Search
Conduit Pharmaceuticals Inc
CDTAdd to Watchlist
0.142USD
-0.012-7.79%
Close 09-22 16:00（ET）
93.72KMarket Cap
0.00P/E TTM
Pre-market 07:14 (ET)0.146USD+0.004+2.82%
Pre-market 07:14 (ET)About Conduit Pharmaceuticals Inc Company
CDT Equity Inc., formerly Conduit Pharmaceuticals, Inc. is a data-driven biotech development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. Through advanced co-crystallization and solidform technologies developed at its Cambridge facility, it is engaged in improving drug properties and has helped in extending the patent life of certain drugs by up to 20 years. Its pipeline includes candidates targeting inflammatory and autoimmune disorders, as well as idiopathic male infertility, dermatology and animal health. It applies proprietary algorithms utilizing AI-powered disease mapping to identify novel repurposing opportunities against a database of over 800 disease signatures. In addition, the Company has initiated pre-clinical in-vitro models to explore new indications, guided by AI-insights without human intervention.
Conduit Pharmaceuticals Inc Profile
Ticker SymbolCDT
Company nameCDT Equity Inc
IPO dateFeb 03, 2022
CEORegan (Andrew)
Number of employees6
Security typeOrdinary Share
Fiscal year-endFeb 03
Address4851 Tamiami Trail North
CityNAPLES
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code34103
Phone16464919132
Websitehttps://www.cdtequity.com/
Ticker SymbolCDT
IPO dateFeb 03, 2022
CEORegan (Andrew)
Company Executives of Conduit Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Ulrik Olsen
Mr. Ulrik Olsen
Independent Director
Independent Director
23.36K
--
Mr. Ulrik Olsen
Mr. Ulrik Olsen
Independent Director
Independent Director
23.36K
--
Ms. Chele Chiavacci Farley
Ms. Chele Chiavacci Farley
Independent Chairman of the Board
Independent Chairman of the Board
7.82K
--
Ms. Chele Chiavacci Farley
Ms. Chele Chiavacci Farley
Independent Chairman of the Board
Independent Chairman of the Board
7.82K
--
Mr. James (Jamie) Bligh
Mr. James (Jamie) Bligh
Chief Executive Officer, Chief Financial Officer, Director
Chief Executive Officer, Chief Financial Officer, Director
240.00
--
Mr. James (Jamie) Bligh
Mr. James (Jamie) Bligh
Chief Executive Officer, Chief Financial Officer, Director
Chief Executive Officer, Chief Financial Officer, Director
240.00
--
Mr. Simon Jeremy Fry
Mr. Simon Jeremy Fry
Independent Director
Independent Director
18.00
--
Mr. Simon Jeremy Fry
Mr. Simon Jeremy Fry
Independent Director
Independent Director
18.00
--
Dr. Freda Lewis-Hall, M.D.
Dr. Freda Lewis-Hall, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Andrew Regan
Dr. Andrew Regan
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Ulrik Olsen
Mr. Ulrik Olsen
Independent Director
Independent Director
23.36K
--
Mr. Ulrik Olsen
Mr. Ulrik Olsen
Independent Director
Independent Director
23.36K
--
Ms. Chele Chiavacci Farley
Ms. Chele Chiavacci Farley
Independent Chairman of the Board
Independent Chairman of the Board
7.82K
--
Ms. Chele Chiavacci Farley
Ms. Chele Chiavacci Farley
Independent Chairman of the Board
Independent Chairman of the Board
7.82K
--
Mr. James (Jamie) Bligh
Mr. James (Jamie) Bligh
Chief Executive Officer, Chief Financial Officer, Director
Chief Executive Officer, Chief Financial Officer, Director
240.00
--
Mr. James (Jamie) Bligh
Mr. James (Jamie) Bligh
Chief Executive Officer, Chief Financial Officer, Director
Chief Executive Officer, Chief Financial Officer, Director
240.00
--
FAQs
Who are the top five shareholders of Conduit Pharmaceuticals Inc?
The top five shareholders of Conduit Pharmaceuticals Inc are: Mr. Ulrik Olsen
How many institutions hold shares of Conduit Pharmaceuticals Inc (CDT)?
As of 2026Q1, 71 institutions hold shares of Conduit Pharmaceuticals Inc, with a combined market value of approximately 4.64K, accounting for 0.10% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 2745.00.